Cian Healthcare Ltd542678Corporate

Pharmaceuticals Latest results: Mar 2026 13 quarters of data

₹17.06

MCap ₹43 Cr

Cian Healthcare Ltd — Stock analysis & AI research Cian Healthcare Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹17 Cr

Sales · Mar 2026

+41.7% YoY

₹-3 Cr

Operating Profit · Mar 2026

+40.0% YoY

-17.6%

OPM % · Mar 2026

+57.8% YoY

₹-18 Cr

Net Profit · Mar 2026

-125.0% YoY

₹-7.19

EPS · Mar 2026

-132.7% YoY

📝 Cian Healthcare Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Cian Healthcare Ltd reported revenue of ₹17 crore for the quarter ended March 2026 (Q4 FY26), up 41.7% from ₹12 crore in the same quarter last year.

The company reported a net loss of ₹18 crore, against a net loss of ₹8 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-7.19.

Operating profit stood at ₹-3 crore — an operating margin (OPM) of -17.6%, compared with -41.7% in the year-ago quarter.

Valuation snapshot

At the current price of ₹17.06, 542678 has a market capitalisation of ₹43 crore.

Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 95.00%, domestic institutional investors (DIIs) 0.00%, public shareholders 5.00% of Cian Healthcare Ltd.

Promoter holding rose from 27.11% to 95.00% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹43 Cr

Current Price ?

₹17.1

P/E ?

N/A

Industry P/E ?

22.40

P/B ?

4.74

P/S ?

N/A

P/FCF ?

1.47

Enterprise Value ?

₹72 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

-16.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹17 Cr

PAT — latest qtr ?

₹-18 Cr

YoY qtr sales growth ?

41.7%

YoY qtr profit growth ?

-125.0%

Sales growth (3y) ?

-26%

Sales growth (5y) ?

-17%

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹29 Cr

Debt to Equity ?

3.22

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

95.00%

Change in promoter holding ?

67.89%

Pledged percentage ?

N/A

Market

Return 3 months ?

106.5%

Return 6 months ?

-76.6%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Mar 2026	YoY %	QoQ %
Sales	29	28	39	35	47	31	38	31	33	62	19	12	17	+41.7%	—
Operating Profit	3	4	5	7	3	1	5	7	4	11	-1	-5	-3	+40.0%	—
Other Income	0	1	0	0	0	0	1	0	0	0	-12	0	-13	—	—
Interest	4	4	4	4	3	3	3	3	3	6	2	1	0	-100.0%	—
Depreciation	2	3	2	1	2	2	3	3	3	5	2	2	2	+0.0%	—
Profit Before Tax	-2	-2	-1	2	-2	-4	0	2	-1	0	-18	-8	-18	-125.0%	—
Net Profit	-2	-2	-1	1	-2	-4	0	2	-1	0	-18	-8	-18	-125.0%	—
EPS	-0.86	-0.75	-0.46	0.48	-0.72	-1.54	0.19	0.62	-0.59	0.10	-7.30	-3.09	-7.19	-132.7%	—
OPM %	10.3%	14.3%	12.8%	20.0%	6.4%	3.2%	13.2%	22.6%	12.1%	17.7%	-5.3%	-41.7%	-17.6%	+57.8%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	25	25	25	25	+0.0%
Reserves	32	33	7	-16	-328.6%
Borrowings	61	56	55	29	-47.3%
Other Liabilities	42	47	69	24	-65.2%
Total Liabilities	160	161	156	62	-60.3%
Fixed Assets	45	39	35	32	-8.6%
CWIP	14	15	15	6	-60.0%
Investments	5	5	5	0	-100.0%
Other Assets	97	102	101	23	-77.2%
Total Assets	160	161	156	62	-60.3%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	5	12	21	21	+0.0%
Cash from Investing Activity	3	-1	-0	13	—
Cash from Financing Activity	-7	-10	-4	-50	-1150.0%
Net Cash Flow	-0	-0	17	-17	-200.0%
Free Cash Flow	4	11	20	29	+45.0%
CFO/OP	37%	106%	-315%	-296%	+6.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	140	121	206	163	-20.9%
Inventory Days	400	486	420	82	-80.5%
Days Payable	296	371	671	219	-67.4%
Cash Conversion Cycle	244	236	-45	26	+157.8%
Working Capital Days	41	26	-729	-96	+86.8%
ROCE %	7%	5%	-11%	-16%	-45.5%

👥 Shareholding (latest 4 periods)

Metric	Sep 2024	Mar 2025	Sep 2025	Mar 2026	% Chg
Promoters	27.11%	27.11%	27.11%	95.00%	+250.4%
DIIs	0.00%	0.00%	0.00%	0.00%	—
Public	72.90%	72.89%	72.89%	5.00%	-93.1%
No. of Shareholders	1,088	1,501	1,662	1,683	+1.3%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	542678 Cian Healthcare	₹19.80	43	—	—	—	—	—	—	—	41.7%	-125.0%

❓ Frequently asked questions

What was Cian Healthcare Ltd's revenue in Q4 FY26?